Sign in
Active, not recruitingPhase 3

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Key facts

Who runs it
Kissei Pharmaceutical Co., Ltd.
Where
Japan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
142 people, planned
Started
15 Aug 2025
Expected to end
31 Mar 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • KPS-0373
  • Placebo
Record updated
4 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Japanese SCD patients with mild to moderate ataxia

Who cannot take part

  • Patients with secondary ataxia
  • Patients with clinically significant hepatic, renal, or cardiovascular dysfunction

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.

The 2 groups in the trial

  • KPS-0373 groupTreatment being tested

    One KPS-0373 2.4 mg tablet is orally administered once daily after breakfast.

    Treatment: KPS-0373

  • Placebo groupPlacebo, for comparison

    One placebo tablet is orally administered once daily after breakfast.

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase III Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
Record updated
4 September 2026